Trials / Recruiting
RecruitingNCT07311850
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,500 (estimated)
- Sponsor
- Metsera, a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MET097 | Once-weekly MET097 administered via subcutaneous injection |
| DRUG | Placebo | Once-weekly placebo administered via subcutaneous injection |
Timeline
- Start date
- 2025-12-29
- Primary completion
- 2027-09-01
- Completion
- 2028-05-01
- First posted
- 2025-12-31
- Last updated
- 2026-02-17
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07311850. Inclusion in this directory is not an endorsement.